Levodopa-carbidopa intestinal gel infusion (LCIG) in Parkinson disease with genetic mutations.

MLA

Balestrino, R., et al. “Levodopa-Carbidopa Intestinal Gel Infusion (LCIG) in Parkinson Disease with Genetic Mutations.” Neurological Sciences, vol. 45, no. 4, Apr. 2024, pp. 1489–97. EBSCOhost, https://doi.org/10.1007/s10072-023-07173-1.

APA

Balestrino, R., Martone, T., Toffoli, M., Montanaro, E., Fabbri, M., Artusi, C. A., Romagnolo, A., Zibetti, M., Rizzone, M., Goldwurm, S., Lopiano, L., & Schapira, A. H. V. (2024). Levodopa-carbidopa intestinal gel infusion (LCIG) in Parkinson disease with genetic mutations. Neurological Sciences, 45(4), 1489–1497. https://doi.org/10.1007/s10072-023-07173-1

Chicago

Balestrino, R., T. Martone, M. Toffoli, E. Montanaro, M. Fabbri, C. A. Artusi, A. Romagnolo, et al. 2024. “Levodopa-Carbidopa Intestinal Gel Infusion (LCIG) in Parkinson Disease with Genetic Mutations.” Neurological Sciences 45 (4): 1489–97. doi:10.1007/s10072-023-07173-1.